 |
|
Prognostic Factors in Leukocytoclastic Vasculitis
A Clinicopathologic Study of 160 Patients
Gemma Sais, MD;
Antonio Vidaller, MD;
Anna Jucglà, MD;
Octavio Servitje, MD;
Enric Condom, MD;
Jordi Peyrí, MD
Arch Dermatol. 1998;134:309-315.
Objective To analyze risk factors for systemic involvement and long-term course in leukocytoclastic vasculitis.
Design A clinicopathological study of 160 patients with leukocytoclastic vasculitis followed up for at least 3 years. Univariate and multivariate analysis were conducted by logistic regression methods.
Setting The Bellvitge Hospital, a referral center in Barcelona, Spain.
Patients One hundred sixty patients with cutaneous leukocytoclastic vasculitis. Patients in the categories cutaneous/systemic vasculitis and acute/chronic cutaneous vasculitis were selected for comparative analysis.
Main Outcome Measures Clinical, laboratory, and histopathological findings.
Results Of 89 females and 71 males, aged 14 to 89 years, systemic involvement was documented in 20% of cases. Perinuclear-staining antineutrophil cytoplasmic autoantibodies were found in 21% of patients and cryoglobulins in 25.4%. Of the patients, 1.9% died of systemic vasculitis. The average duration of cutaneous lesions was 27.9 months. In 67.2%, a cause or associated condition was identified. Of the skin specimens, 59.6% showed vasculitis limited to superficial dermal vessels. Direct immunofluorescence was positive in 84.3% of cases. In the multivariate analysis, paresthesia, fever, and absence of painful lesions were found to be risk factors for systemic involvement. Cryoglobulins, arthralgia, and normal temperature were risk factors for chronic cutaneous disease.
Conclusion Our results identify prognostic factors in leukocytoclastic vasculitis and may provide some aid in the management of this heterogeneous group of patients.
From the Departments of Dermatology (Drs Sais, Jucglà, Servitje, and Peyrí), Internal Medicine (Dr Vidaller), and Pathology (Dr Condom), Hospital Prínceps d'Espanya, Ciutat Sanitària i Universitària de Bellvitge, Departament de Medicina, Universitat de Barcelona, Barcelona, Spain.
RELATED ARTICLE
Cutaneous Vasculitis: What Have We Learned in the Past 20 Years?
Jeffrey P. Callen
Arch Dermatol. 1998;134(3):355-357.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Famciclovir-Induced Leukocytoclastic Vasculitis
Te et al.
The Annals of Pharmacotherapy 2008;42:1323-1326.
ABSTRACT
| FULL TEXT
Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis.
Bahrami et al.
Arch Dermatol 2006;142:155-161.
ABSTRACT
| FULL TEXT
Prognostic Factors in Leukocytoclastic Vasculitis: What Is the Role of Antineutrophil Cytoplasmic Antibody?
Papi et al.
Arch Dermatol 1999;135:714-715.
FULL TEXT
Outcome Predictors in Leukocytoclastic Vasculitis
Journal Watch Dermatology 1998;1998:5-5.
FULL TEXT
Cutaneous Vasculitis: What Have We Learned in the Past 20 Years?
Callen
Arch Dermatol 1998;134:355-357.
FULL TEXT
Antineutrophil Cytoplasmic Antibodies in Leukocytoclastic Vasculitis
Sais et al.
Arch Dermatol 1998;134:239-240.
FULL TEXT
|
